BioCentury
ARTICLE | Clinical News

Afuresertib: Phase I/II data

June 13, 2016 7:00 AM UTC

Data from 29 patients with recurrent ovarian cancer in the Phase I portion of an open-label, international Phase I/II trial showed that once-daily oral afuresertib plus paclitaxel and carboplatin led ...